We are live on ! Find out more
RCUS icon

Arcus Biosciences

131 hedge funds and large institutions have $1.68B invested in Arcus Biosciences in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $4.84M | Put options by funds: $1.37M

50% more funds holding in top 10

Funds holding in top 10: 69 (+3)

36% more capital invested

Capital invested by funds: $1.24B → $1.68B (+$445M)

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

4% more ownership

Funds ownership: 63.62%67.62% (+4%)

1% more funds holding

Funds holding: 130131 (+1)

29% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 51

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.29%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.16%
New
17
Increased
36
Reduced
51
Closed
15
Calls
$4.84M
Puts
$1.37M
Net Calls
+$3.47M
Net Calls Change
+$8.16M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
1
EcoR1 Capital
California
$179M +$55.6M +1,787,112 +54%
BlackRock
2
BlackRock
New York
$147M +$5.11M +164,232 +4%
AI
3
Alphabet Inc
California
$143M -$16M -513,343 -11%
PHS
4
PFM Health Sciences
California
$120M -$2.09M -67,250 -2%
BI
5
BVF Inc
California
$113M +$13.4M +432,000 +15%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$108M
Vanguard Group
7
Vanguard Group
Pennsylvania
$86M +$1.15K +37 +0%
State Street
8
State Street
Massachusetts
$81.3M -$11M -354,071 -13%
BC
9
Boxer Capital
California
$72.7M
IFA
10
Invus Financial Advisors
New York
$64.2M
WP
11
Woodline Partners
California
$59.2M +$1.11M +35,545 +2%
PAMS
12
Pictet Asset Management (Switzerland)
Switzerland
$52.3M +$46.7M +1,501,228 New
Franklin Resources
13
Franklin Resources
California
$50.8M +$18.1M +581,311 +66%
OCA
14
Octagon Capital Advisors
New York
$33.8M +$6.54M +210,000 +28%
BNP Paribas Asset Management
15
BNP Paribas Asset Management
France
$27.4M +$14.7M +473,310 +152%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$27.3M +$362K +11,622 +2%
SAM
17
Sectoral Asset Management
Quebec, Canada
$25.8M +$2.02M +64,750 +10%
TCM
18
TimesSquare Capital Management
New York
$22.7M -$1.1M -35,300 -5%
Northern Trust
19
Northern Trust
Illinois
$22.3M -$870K -27,949 -4%
Macquarie Group
20
Macquarie Group
Australia
$16.1M -$44.1K -1,418 -0.3%
BCPEMI
21
Bain Capital Public Equity Management II
Massachusetts
$15.9M +$14.2M +454,863 New
Charles Schwab
22
Charles Schwab
California
$12.4M +$332K +10,682 +3%
Ameriprise
23
Ameriprise
Minnesota
$10.4M
Two Sigma Advisers
24
Two Sigma Advisers
New York
$10.2M -$2.65M -85,200 -23%
GGHC
25
Gilder Gagnon Howe & Co
New York
$10.1M -$189K -6,085 -2%

RCUS Hedge Fund Activity: Q3 2021 in Review

131 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2021, worth a combined $1.68B — up 36% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RCUS positions and 15 closed out — a net gain of 2 holders — while 36 added to existing stakes and 51 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $55.6M. The largest seller was Alphabet Inc, cutting an estimated $16M.

  • 131 institutional investors held Arcus Biosciences (RCUS) as of Q3 2021, up from 130 in Q2 2021.
  • Funds reported $1.68B of Arcus Biosciences stock for Q3 2021, up 36% quarter-over-quarter.
  • 17 funds opened new Arcus Biosciences positions in Q3 2021 and 15 closed out, a net change of +2 holders.
  • The largest Arcus Biosciences buyer in Q3 2021 was EcoR1 Capital, an estimated $55.6M added.
  • The largest Arcus Biosciences seller in Q3 2021 was Alphabet Inc, an estimated $16M sold.

Based on aggregated 13F filings for Q3 2021.